ATE304369T1 - Intakte oder zerstörte insektenzellen als antigenadjuvant - Google Patents

Intakte oder zerstörte insektenzellen als antigenadjuvant

Info

Publication number
ATE304369T1
ATE304369T1 AT98957566T AT98957566T ATE304369T1 AT E304369 T1 ATE304369 T1 AT E304369T1 AT 98957566 T AT98957566 T AT 98957566T AT 98957566 T AT98957566 T AT 98957566T AT E304369 T1 ATE304369 T1 AT E304369T1
Authority
AT
Austria
Prior art keywords
insect cells
adjuvant
antigen
intact
destroyed
Prior art date
Application number
AT98957566T
Other languages
English (en)
Inventor
Gale Eugene Smith
James Debartolomeis
Andrei Igorevitch Voznesenski
Original Assignee
Protein Sciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25510359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE304369(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Protein Sciences Corp filed Critical Protein Sciences Corp
Application granted granted Critical
Publication of ATE304369T1 publication Critical patent/ATE304369T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT98957566T 1997-11-07 1998-11-04 Intakte oder zerstörte insektenzellen als antigenadjuvant ATE304369T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/965,698 US6224882B1 (en) 1997-11-07 1997-11-07 Insect cells or fractions as adjuvant for antigens
PCT/US1998/023472 WO1999024049A1 (en) 1997-11-07 1998-11-04 Insect cells or fractions as adjuvant for antigens

Publications (1)

Publication Number Publication Date
ATE304369T1 true ATE304369T1 (de) 2005-09-15

Family

ID=25510359

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98957566T ATE304369T1 (de) 1997-11-07 1998-11-04 Intakte oder zerstörte insektenzellen als antigenadjuvant

Country Status (11)

Country Link
US (1) US6224882B1 (de)
EP (2) EP1033995B1 (de)
AT (1) ATE304369T1 (de)
AU (1) AU1379599A (de)
CA (1) CA2309003C (de)
DE (1) DE69831594T2 (de)
DK (1) DK1033995T3 (de)
ES (1) ES2248921T3 (de)
NZ (1) NZ504424A (de)
PT (1) PT1033995E (de)
WO (1) WO1999024049A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637566A (en) * 1988-08-24 1997-06-10 Southern Cross Biotech Pty. Ltd. Method of improving carcass quality by administering growth hormone
US6342216B1 (en) * 1999-03-17 2002-01-29 The Board Of Regents, The University Of Texas System Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
AUPQ233799A0 (en) 1999-08-19 1999-09-09 Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales Recombinant sub-unit vaccine
JP2003535065A (ja) * 2000-05-31 2003-11-25 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 特異的免疫の誘導のためのアジュバント調製
US20060228326A1 (en) * 2002-10-22 2006-10-12 Fidler Isaiah J Active specific immunotherapy of cancer metastasis
EP1606419A1 (de) 2003-03-18 2005-12-21 Quantum Genetics Ireland Limited Systeme und methoden zur erhohung der milchproduktion in tieren
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
US8541003B2 (en) 2003-06-20 2013-09-24 Protein Sciences Corporation Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US8080255B2 (en) * 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
US8992939B2 (en) 2003-07-11 2015-03-31 Novavax, Inc. Highly efficient influenza matrix (M1) proteins
US8506967B2 (en) 2003-07-11 2013-08-13 Novavax, Inc. Functional influenza virus like particles (VLPs)
WO2005049794A2 (en) 2003-11-13 2005-06-02 University Of Georgia Research Foundation, Inc. Methods of characterizing infectious bursal disease virus
WO2005112544A2 (en) 2004-02-19 2005-12-01 The Governors Of The University Of Alberta Leptin promoter polymorphisms and uses thereof
RS51324B (sr) 2005-04-25 2010-12-31 Merial Ltd. Vakcine protiv nipah virusa
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
CA2621666A1 (en) * 2005-09-09 2007-03-15 Universitaet Zuerich Antigens for vaccination against and detection of mycoplasma suis
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
EP3147296A1 (de) 2005-11-14 2017-03-29 Merial, Inc. Gentherapie für nierenversagen
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
WO2008009115A1 (en) * 2006-07-18 2008-01-24 Ottawa Health Research Institute Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses
EP3542815A1 (de) 2008-11-28 2019-09-25 Boehringer Ingelheim Animal Health USA Inc. Rekombinanter vogelgrippeimpfstoff und verwendungen davon
EP2414386B1 (de) 2009-04-03 2016-01-27 Merial Limited Vogelimpfstoffe mit newcastle-krankheit-vektor
EP2611460B1 (de) 2010-08-31 2016-10-05 Merial, Inc. Auf das virus der newcastle-krankheit gerichtete herpesvirus-impfstoffe
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
US20140296248A1 (en) 2011-04-04 2014-10-02 Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
EP2694678A2 (de) 2011-04-04 2014-02-12 Netherland Cancer Institute Verfahren und zusammensetzungen zur vorhersage der resistenz gegenüber einer antikrebsbehandlung
US9216213B2 (en) 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
WO2012149038A1 (en) 2011-04-25 2012-11-01 Advanced Bioscience Laboratories, Inc. Truncated hiv envelope proteins (env), methods and compositions related thereto
CA2837375C (en) 2011-06-01 2019-07-16 Merial Limited Needle-free administration of prrsv vaccines
MX350096B (es) 2011-08-12 2017-08-25 Merial Inc Preservación asistida con vacío de productos biológicos, en particular de vacunas.
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
HK1216006A1 (zh) 2013-03-12 2016-10-07 Boehringer Ingelheim Animal Health USA Inc. 反向遺傳學施馬倫貝格病毒疫苗組合物，和其使用方法
ES2882374T3 (es) 2013-05-08 2021-12-01 Pharmgate Biologics Inc Vacuna para PCV2 y micoplasma
WO2016073410A1 (en) 2014-11-03 2016-05-12 Merial, Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
ES3050936T3 (en) 2015-06-23 2025-12-23 Boehringer Ingelheim Vetmedica Gmbh Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof
WO2017031120A1 (en) 2015-08-20 2017-02-23 Merial, Inc. Fcv recombinant vaccines and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US5019384A (en) 1986-06-30 1991-05-28 Massachusetts Institute Of Technology Immunonodulating compositions and their use
IE872748L (en) 1986-10-16 1988-04-16 Arjomari Europ Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
DK0506868T4 (da) 1989-12-22 2004-04-26 Mikrogen Molekularbiol Entw Immunologisk aktive proteiner fra Borrelia burgdorferi, tilhørende testkits og vaccine
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5503834A (en) 1990-11-20 1996-04-02 Virogenetics Corporation Measles virus recombinant poxvirus vaccine
FI933580A7 (fi) 1991-02-15 1993-10-13 Uab Research Foundation Pneumokokkiproteiinin rakennegeeni
AU672581B2 (en) 1991-03-07 1996-10-10 Virogenetics Corporation Immunodeficiency virus recombinant poxvirus vaccine
US5766597A (en) 1991-03-07 1998-06-16 Virogenetics Corporation Malaria recombinant poxviruses
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
WO1993003145A1 (en) 1991-07-26 1993-02-18 Virogenetics Corporation Infectious bursal disease virus recombinant poxvirus vaccine
US6113914A (en) 1991-08-15 2000-09-05 Smithkline Beecham Biologicals (S.A.) Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
PT100980B (pt) 1991-10-18 1999-07-30 Connaught Lab Proteinas recombinantes de borrelia, seu processo de producao, vacina contra infeccao por borrelia e agente de imunodiagnostico para a sua deteccao
ES2194010T3 (es) 1991-10-22 2003-11-16 Symbicom Ab Mejoras en el diagnostico y profilaxis de la borrelia burgdorferi.
JPH06166635A (ja) * 1992-06-18 1994-06-14 San Five Kk 免疫アジュバント
US5529780A (en) 1994-03-30 1996-06-25 Virogenetics Corporation Nucleotide and amino acid sequences of canine herpesvirus gB and gC
US5528771A (en) 1994-07-29 1996-06-25 Yudin; Beniamin Back support
EP0773993A4 (de) 1994-08-19 2000-07-05 Gen Hospital Corp Gentechnisch veränderte schweine-zellen
KR20070011489A (ko) 2004-04-13 2007-01-24 도날드슨 캄파니 인코포레이티드 액체 여과용 필터 카트리지
CA2943383A1 (en) 2014-03-21 2015-09-24 Avery Dennison Corporation Faceless labels and related systems and methods

Also Published As

Publication number Publication date
DE69831594D1 (de) 2006-01-26
NZ504424A (en) 2001-09-28
EP1033995B1 (de) 2005-09-14
EP1033995A1 (de) 2000-09-13
AU1379599A (en) 1999-05-31
DK1033995T3 (da) 2006-01-30
US6224882B1 (en) 2001-05-01
PT1033995E (pt) 2005-11-30
WO1999024049A1 (en) 1999-05-20
ES2248921T3 (es) 2006-03-16
CA2309003C (en) 2012-10-02
DE69831594T2 (de) 2006-07-06
EP1611897A2 (de) 2006-01-04
WO1999024049A9 (en) 1999-08-12
EP1611897A3 (de) 2007-08-15
EP1033995A4 (de) 2001-01-10
CA2309003A1 (en) 1999-05-20

Similar Documents

Publication Publication Date Title
DE69831594D1 (de) Intakte oder zerstörte insektenzellen als antigenadjuvant
ATE229978T1 (de) Helicobacter proteine und impstoffe
ATE295895T1 (de) Genetischer impfstoff gegen den immunschwäche virus
DE59010925D1 (de) Toxoplasma gondii-Antigene, ihre Herstellung und ihre Verwendung
ATE90388T1 (de) Schuetzendes peptid-antigen.
DK0909323T3 (da) Helicobacter pylori-bakterioferritin
DE3585578D1 (de) Hepatitisoberflaechenantigenpartikelvakzin.
PT586076E (pt) Vacinas de adenovirus recombinantes
ATE241385T1 (de) Rekombinante adenovirus-vakzinen
DE3585370D1 (de) Kreuzreaktive und schuetzende epitope von circumsporozoit-proteinen.
DE69633919D1 (de) Mehrzweckvakzine gegen umhüllte viren
SE8700466D0 (sv) Vaccines against melanoma
Adreeva et al. On the possibility of using burnt ceramic masses for making up for damaged ceramics
MX9706267A (es) Antigeno de helicobacter pylori.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1033995

Country of ref document: EP